The impact of antidiabetic therapies on cardiovascular disease (Q36025991)

11 August 2017

1 reference

title

The impact of antidiabetic therapies on cardiovascular disease (English)

1 reference

11 August 2017

Brandy Panunti

1

1 reference

11 August 2017

Biju Kunhiraman

series ordinal

2

1 reference

11 August 2017

Vivian Fonseca

series ordinal

3

1 reference

11 August 2017

1 February 2005

1 reference

Current Atherosclerosis Reports

11 August 2017

1 reference

11 August 2017

7

1 reference

11 August 2017

50-57

1 reference

11 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-005-0075-4

11 August 2017

0 references

cites work

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-005-0075-4

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

12 December 2020

Insulin therapy for the critically ill patient

1 reference

12 December 2020

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

1 reference

12 December 2020

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features

1 reference

12 December 2020

Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting

1 reference

12 December 2020

Low density lipoprotein particle size and risk factors of insulin resistance syndrome

1 reference

12 December 2020

Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients

1 reference

12 December 2020

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

12 December 2020

Etiology and prevalence of hypertension in diabetic patients

1 reference

12 December 2020

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Inf

1 reference

12 December 2020

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

1 reference

12 December 2020

Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction

1 reference

12 December 2020

Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction

1 reference

12 December 2020

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

12 December 2020

Roles of PPARs in health and disease.

1 reference

12 December 2020

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

1 reference

12 December 2020

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

12 December 2020

Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

1 reference

12 December 2020

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

12 December 2020

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention

1 reference

12 December 2020

Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial

1 reference

12 December 2020

Nephropathy in diabetes

1 reference

12 December 2020

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.

1 reference

12 December 2020

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

12 December 2020

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

1 reference

12 December 2020

The association between insulin resistance and endotheliopathy

1 reference

12 December 2020

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

12 December 2020

Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results

1 reference

12 December 2020

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

12 December 2020

Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?

1 reference

12 December 2020

The effect of occult diabetic status and oral glucose intake on brachial artery vasoactivity in patients with peripheral vascular disease.

1 reference

12 December 2020

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

1 reference

12 December 2020

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

1 reference

12 December 2020

Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study.

1 reference

12 December 2020

1 reference

12 December 2020

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

12 December 2020

An overview of metformin in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions

1 reference

12 December 2020

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Evidence for a potent antiinflammatory effect of rosiglitazone

1 reference

12 December 2020

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

12 December 2020

Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats

1 reference

12 December 2020

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

12 December 2020

Diabetes and decline in heart disease mortality in US adults.

1 reference

12 December 2020

10.1007/S11883-005-0075-4

Identifiers

DOI

1 reference

release_v7zdxt5arrgnnmjotsdy6zrefe

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v7zdxt5arrgnnmjotsdy6zrefe

24 November 2022

mapped directly with Wikidata item

1 reference